Korean J Hematol 1997; 32(3):
Published online September 30, 1997
© The Korean Society of Hematology
김준환, 이경희, 현명수
연세대학교 의과대학 내과학교실
Background: Myelodysplastic syndrome(MDS) is a disorder of the hematopoietic pluripotent stem cell. The treatment modality and its prognosis were based on the FAB classification. But, because there is a variation of the clinical course, we evaluated the clinical characteristics and prognostic factors of MDS with score system.
Method : We analyzed age, FAB classification, symptoms, peripheral blood and bone marrow findings of MDS patients for evaluation of clinical course and prognosis.
Results:
1) Age & Sex : Male to female ratio was 19:11, and age distribution was mainly over 5th decade(77%).
2) Subtype : The most common subtype was RAEB(43%), followed by RA(23%),RAEBT(17%), CMML(10%), and RARS(6.7%).
3) Initial symptom : The most common symptom was exertional dyspnea, followed by general weakness, headache, dizziness, and febrile sensation.
4) Peripheral blood Anemia(< 10g/dL) was noted in 90%, leukopenia(<2.5×10 9/L) in 36.6%, and thrombocytopenia(<100×10 9/L) in 73.3%.
5) Bone marrow finding : Hypocellularity was noted in 23%, normocellularity in 13%, hypercellularity in 63%. Bone marrow fibrosis was noted in 1 case of CMML.
6) Duration of mean follow-up period was 12.3 months and mean survival rate was 17.4 months .
7) The score of Sanz and Gattermann in the patient with RAEB and RAEBT were significantly higher than those of the patients with RA and RARS. Transformation to AML was seen in 5 cases with group C of Gattermann score.
8) With anabolic steroid therapy in 10 cases of RA & RARS, 2 cases were clinically improved, and with low dose Ara-C therapy in 5 cases, one case in RARS and another in RAEB were completely remixed but the latter convered to AML after 16 months.
Conclusion: The patients with RA and RARS have longer survival rate than the patients with other types of MDS. The score system of Bournemouth, Sanz and Gattermann were useful in evaluating the prognosis of MDS, being Gattermann score more valuable than those of Bournmouth and Sanz to predict the prognosis of MDS.
Keywords Myelodysplastic syndrome; Score system; Prognostic factor;
Korean J Hematol 1997; 32(3): 398-408
Published online September 30, 1997
Copyright © The Korean Society of Hematology.
김준환, 이경희, 현명수
연세대학교 의과대학 내과학교실
Jun Hwan Kim, Kyung Hee Lee, Myung Soo Hyun
Department of Internal Medicine, Youngnam University, College of Medicine, Taegu, Korea
Background: Myelodysplastic syndrome(MDS) is a disorder of the hematopoietic pluripotent stem cell. The treatment modality and its prognosis were based on the FAB classification. But, because there is a variation of the clinical course, we evaluated the clinical characteristics and prognostic factors of MDS with score system.
Method : We analyzed age, FAB classification, symptoms, peripheral blood and bone marrow findings of MDS patients for evaluation of clinical course and prognosis.
Results:
1) Age & Sex : Male to female ratio was 19:11, and age distribution was mainly over 5th decade(77%).
2) Subtype : The most common subtype was RAEB(43%), followed by RA(23%),RAEBT(17%), CMML(10%), and RARS(6.7%).
3) Initial symptom : The most common symptom was exertional dyspnea, followed by general weakness, headache, dizziness, and febrile sensation.
4) Peripheral blood Anemia(< 10g/dL) was noted in 90%, leukopenia(<2.5×10 9/L) in 36.6%, and thrombocytopenia(<100×10 9/L) in 73.3%.
5) Bone marrow finding : Hypocellularity was noted in 23%, normocellularity in 13%, hypercellularity in 63%. Bone marrow fibrosis was noted in 1 case of CMML.
6) Duration of mean follow-up period was 12.3 months and mean survival rate was 17.4 months .
7) The score of Sanz and Gattermann in the patient with RAEB and RAEBT were significantly higher than those of the patients with RA and RARS. Transformation to AML was seen in 5 cases with group C of Gattermann score.
8) With anabolic steroid therapy in 10 cases of RA & RARS, 2 cases were clinically improved, and with low dose Ara-C therapy in 5 cases, one case in RARS and another in RAEB were completely remixed but the latter convered to AML after 16 months.
Conclusion: The patients with RA and RARS have longer survival rate than the patients with other types of MDS. The score system of Bournemouth, Sanz and Gattermann were useful in evaluating the prognosis of MDS, being Gattermann score more valuable than those of Bournmouth and Sanz to predict the prognosis of MDS.
Keywords: Myelodysplastic syndrome, Score system, Prognostic factor,
Byung Soo Kim, Jae Hong Suh, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim
Korean J Hematol 1995; 30(2): 279-287Junshik Hong, Yoo Jin Lee, Sung Hwa Bae, Jun Ho Yi, Sungwoo Park, Myung Hee Chang, Young Hoon Park, Shin Young Hyun, Joo-Seop Chung, Ji Eun Jang, Joo Young Jung, So-Yeon Jeon, Seo-Young Song, Hawk Kim, Dae Sik Kim, Sung-Hyun Kim, Min Kyoung Kim, Sang Hoon Han, Seonyang Park, Yoo-Jin Kim, Je-Hwan Lee, on behalf of the AML/MDS Working Party of the Korean Society of Hematology
Blood Res 2021; 56(2): 102-108Meerim Park
Blood Res 2021; 56(S1): S34-S38